This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Cardiovascular Disease/ Myocardial Infarction  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: The US Food and Drug Administration recently announced the premature discontinuation of ADAPT due to an apparent increase in adverse cardiovascular events associated with naproxen.¹ Because previous reports have shown naproxen to have a cardioprotective effect, this finding was unexpected and has caused a considerable amount of confusion among practitioners and the public.²

ADAPT and other similar trials evaluating the effect of long term exposure to NSAIDs allow patients to continue receiving cardioprotective doses of aspirin (<325 mg/d) without controlling for allocation between arms, timing of aspirin administration in relationship to the NSAID dose, or dosage form of aspirin used (soluble vs enteric coated).³ Catella-Lawson et al⁴ observed that administration of ibuprofen (a propionic acid derivative similar to naproxen) with or prior to aspirin negates the antiplatelet effect of aspirin by binding to a serine residue in the channel that aspirin must traverse before it can access . . . [Full Text of this Article]

David F. Lehmann, MD, PharmD
lehmannd@upstate.edu
State University of New York Upstate Medical University
Syracuse

RELATED ARTICLES

Arthritis Medications and Cardiovascular Events
Mario Guslandi
JAMA. 2005;293(16):1975-1976.
EXTRACT | FULL TEXT  

Arthritis Medications and Cardiovascular Events
Simeon Pollack
JAMA. 2005;293(16):1976.
EXTRACT | FULL TEXT  

Arthritis Medications and Cardiovascular Events—Reply
Eric J. Topol
JAMA. 2005;293(16):1976-1977.
EXTRACT | FULL TEXT  

Arthritis Medicines and Cardiovascular Events—"House of Coxibs"
Eric J. Topol
JAMA. 2005;293(3):366-368.
EXTRACT | FULL TEXT